Hikma Pharmaceuticals 2016 final results

DividendMax Ltd.

Hikma Pharmaceuticals 2016 final results

2016 financial highlights

Group revenue of $1,950 million, up 35% and up 39% in constant currency

Group core operating profit of $419 million, up 2% and up 14% in constant currency, reflecting strong growth in Injectables and Branded profitability, partially offset by a lower contribution from the Generics business and a step-up in R&D investment across the Group to support sustainable growth

Group reported operating profit of $302 million, down 21% and down 9% in constant currency, reflecting a significant increase in intangible amortisation and exceptional items in 2016

Group core basic earnings per share of 118.5 cents, down 18% and down 5% in constant currency following the issuance of 40 million additional shares in February 2016 in relation to the West-Ward Columbus acquisition

Proposed final dividend of 22 cents per share, and full year dividend of 33 cents per share, up from 32 cents per share for the full year in 2015

Group revenue in 2017 expected to be around $2.2 billion in constant currency

Companies mentioned